EW Stock Cash Flow Statements

Edwards Lifesciences Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Edwards Lifesciences Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2007-06-30	2007-03-31	2006-09-30	2006-06-30	2006-03-31	2005-09-30

cash flows from operating activities
net income	331,500,000	356,400,000	384,300,000	3,069,400,000	365,000,000	351,000,000	369,700,000	383,700,000	305,500,000	340,500,000	398,400,000	343,500,000	406,400,000	373,600,000	335,300,000	340,100,000	489,500,000	338,200,000	309,500,000	325,200,000	-121,900,000	310,600,000	280,200,000	274,700,000	242,300,000	249,700,000	7,000,000	225,900,000	282,700,000	206,600,000	-2,800,000	170,100,000	186,100,000	230,200,000	158,500,000	141,400,000	126,600,000	143,000,000	140,700,000	118,100,000	112,700,000	123,400,000	34,900,000	33,200,000	27,800,000	36,100,000	45,900,000	-45,099,959.3
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	38,100,000	36,600,000	42,600,000	34,500,000	39,600,000	38,500,000	36,700,000	36,900,000	36,100,000	35,200,000	35,400,000	35,400,000	34,100,000	34,700,000	33,000,000	33,600,000	35,800,000	32,400,000	32,600,000	25,600,000	24,500,000	24,500,000	23,900,000	23,100,000	21,700,000	20,600,000	19,900,000	19,200,000	19,200,000	19,100,000	21,200,000	20,700,000	18,900,000	21,100,000	19,100,000	18,200,000	18,000,000	15,900,000	14,500,000	18,500,000	16,800,000	16,000,000	13,700,000	13,400,000	13,800,000	14,200,000	14,200,000	-27,799,958.2
non-cash operating lease cost	6,400,000	6,100,000	6,200,000	6,500,000	7,400,000	7,700,000	7,500,000	7,000,000	6,900,000	6,800,000	6,600,000	6,700,000	6,800,000	7,100,000	7,100,000	7,100,000	7,000,000	7,300,000	7,500,000	7,400,000	6,600,000	6,700,000	6,600,000	6,900,000
stock-based compensation	37,500,000	40,200,000	31,700,000	42,100,000	43,900,000	44,600,000	30,500,000	32,600,000	37,400,000	38,900,000	27,900,000	30,300,000	36,200,000	32,400,000	24,200,000	26,600,000	30,300,000	28,200,000	20,900,000	23,000,000	24,800,000	23,900,000	18,400,000	19,800,000	22,300,000	20,800,000	16,000,000	17,400,000	19,200,000	18,400,000	15,300,000	15,800,000	15,300,000	15,200,000	13,900,000	14,400,000	14,300,000	14,300,000	12,900,000	12,600,000	10,800,000	13,600,000	6,500,000	6,900,000	7,100,000	6,900,000	5,800,000
deferred income taxes	-20,900,000	-24,300,000	-98,500,000	-123,000,000	-66,100,000	-35,800,000	-91,400,000	-46,000,000	-82,900,000	-51,800,000	-105,800,000	-46,300,000	-59,800,000	-42,600,000	-61,500,000	3,900,000	5,400,000	10,800,000	-11,600,000	1,400,000	-42,800,000	3,600,000	2,600,000	-3,400,000	7,100,000	5,800,000	-57,100,000	10,900,000	-12,200,000	31,100,000	-26,300,000	400,000	7,100,000	36,600,000	-34,800,000	-2,800,000	0	200,000	-93,900,000	-3,300,000	-1,900,000	4,100,000	600,000	3,100,000			2,700,000
loss on impairment
other	4,700,000	3,600,000	15,700,000	700,000	2,500,000	-500,000	4,000,000	1,600,000	2,400,000	400,000	2,300,000	1,300,000	-16,200,000	20,400,000	-7,100,000	-3,100,000	-10,500,000	-2,700,000	-4,100,000	-4,200,000	-9,900,000	14,700,000	2,000,000	2,900,000	-700,000	-7,000,000	10,000,000	1,000,000	1,000,000	1,000,000	-4,000,000	-9,100,000	4,900,000	2,000,000	1,600,000	3,500,000	2,100,000	700,000	1,100,000	9,200,000	900,000	-200,000	1,400,000	500,000	1,200,000	-4,900,000	5,200,000	-11,499,984.7
changes in operating assets and liabilities:
accounts and other receivables	-24,900,000	-43,700,000	105,900,000	47,300,000	23,000,000	-55,000,000	-18,200,000	1,300,000	-46,800,000	-77,500,000	-1,100,000	-5,300,000	-19,900,000	-57,800,000	6,800,000	38,000,000	-46,400,000	-89,500,000	51,100,000	-30,700,000	25,700,000	-4,200,000	-17,700,000	18,900,000	-43,400,000	-45,800,000	-28,400,000	-2,900,000	-27,300,000	29,900,000	10,500,000	56,100,000	11,000,000	-81,500,000	-1,900,000	9,900,000	-32,500,000	-32,200,000	-10,000,000	11,200,000	-3,000,000	-36,500,000					2,100,000
inventories	41,600,000	-100,000	-51,200,000	-41,200,000	-94,200,000	-69,500,000	-99,300,000	-76,000,000	-80,900,000	-32,800,000	-62,300,000	-65,300,000	-61,800,000	-24,000,000	-6,600,000	8,100,000	15,000,000	2,500,000	-2,400,000	-19,000,000	-64,000,000	-35,200,000	-21,500,000	-22,000,000	-32,500,000	-29,400,000	-22,200,000	-23,000,000	-17,200,000	-3,300,000	-14,200,000	-37,600,000	-47,900,000	-24,300,000	-22,500,000	-28,400,000	-10,100,000	-4,600,000	-11,600,000	-23,800,000	-13,400,000	-18,900,000		900,000
accounts payable and accrued liabilities	103,700,000	-103,400,000	-3,100,000	29,900,000	151,800,000	-89,100,000	33,400,000	36,400,000	121,400,000	-45,200,000	34,300,000	26,000,000	27,500,000	-109,200,000	31,100,000	79,300,000	94,100,000	-9,300,000	-30,600,000	81,400,000	9,100,000	-144,400,000	45,700,000	81,400,000	51,600,000	-242,200,000	188,500,000	93,200,000	28,800,000	-118,000,000	36,600,000	112,400,000	30,400,000	-94,200,000	32,600,000	54,300,000	34,700,000	-47,600,000	-6,500,000	55,200,000	39,800,000	-59,100,000			1,700,000			-9,899,966.5
income taxes	-240,400,000	51,200,000	-488,500,000	671,800,000	-106,900,000	-263,100,000	-112,100,000	75,300,000	-56,200,000	87,200,000	-14,400,000	-40,900,000	-33,200,000	82,900,000	33,000,000	5,800,000	9,100,000	14,100,000	12,700,000	-74,700,000	-23,100,000	32,200,000	26,200,000	20,500,000	12,800,000	-16,300,000	50,800,000	-19,700,000	-182,200,000	-6,700,000	333,400,000	-9,000,000	-65,000,000	19,000,000	32,200,000	12,000,000	36,100,000	24,800,000	70,600,000	19,000,000	18,300,000	26,600,000
prepaid expenses and other current assets	-13,900,000	10,600,000	-4,700,000	-12,700,000	13,000,000	27,100,000	-18,100,000	-20,300,000	-19,600,000	-23,800,000	-20,200,000	-5,400,000	24,000,000	1,700,000	6,400,000	1,100,000	5,800,000	-5,400,000	-6,400,000	-21,800,000	5,400,000	-5,700,000	-4,300,000	-6,400,000	1,100,000	2,800,000			14,900,000	-26,400,000	-10,000,000	-1,200,000	4,900,000	-3,600,000	1,900,000	-500,000	-10,400,000	-3,600,000	-9,100,000	-700,000	1,100,000	8,500,000
intellectual property agreement accrual	-12,500,000	-36,700,000	-12,500,000	-12,500,000	-6,600,000	-5,200,000	-7,000,000	-11,500,000	-43,800,000	29,300,000
net cash from operating activities	290,200,000	280,400,000	-127,500,000	351,800,000	371,500,000	-53,500,000	136,600,000	411,500,000	33,600,000	314,100,000	282,800,000	309,900,000	332,200,000	293,300,000	373,600,000	531,900,000	526,100,000	300,500,000	400,000,000	216,100,000	231,200,000	207,000,000	399,400,000	437,300,000	341,200,000	1,500,000	293,000,000	342,300,000	140,200,000	151,300,000	363,900,000	310,800,000	197,700,000	128,300,000	201,100,000	205,900,000	190,300,000	107,100,000	103,800,000	202,500,000	170,100,000	73,300,000	37,800,000	36,100,000	60,200,000	39,600,000	61,000,000	-53,499,907.5
cash flows from investing activities
capital expenditures	-49,300,000	-56,000,000	-49,800,000	-51,900,000	-85,400,000	-65,300,000	-88,300,000	-55,300,000	-47,900,000	-61,500,000	-68,900,000	-59,900,000	-43,100,000	-72,700,000	-89,800,000	-60,700,000	-69,300,000	-106,000,000	-113,200,000	-103,300,000	-108,300,000	-82,200,000	-71,500,000	-76,100,000	-64,600,000	-42,200,000	-57,600,000	-85,100,000	-52,800,000	-43,200,000	-51,900,000	-42,300,000	-58,000,000	-15,900,000	-63,200,000	-48,100,000	-37,100,000	-27,700,000	-37,500,000	-26,000,000	-18,400,000	-20,800,000
free cash flows	240,900,000	224,400,000	-177,300,000	299,900,000	286,100,000	-118,800,000	48,300,000	356,200,000	-14,300,000	252,600,000	213,900,000	250,000,000	289,100,000	220,600,000	283,800,000	471,200,000	456,800,000	194,500,000	286,800,000	112,800,000	122,900,000	124,800,000	327,900,000	361,200,000	276,600,000	-40,700,000	235,400,000	257,200,000	87,400,000	108,100,000	312,000,000	268,500,000	139,700,000	112,400,000	137,900,000	157,800,000	153,200,000	79,400,000	66,300,000	176,500,000	151,700,000	52,500,000
investments in unconsolidated affiliates																						-1,400,000				-1,300,000			-1,400,000	-1,800,000		0	100,000	200,000	-2,500,000	-3,100,000	0	-2,000,000				-400,000
purchases of held-to-maturity investments	-6,000,000	-12,800,000	-9,600,000	-22,200,000	-13,300,000	-800,000	-42,900,000	-8,000,000	-3,000,000	-12,500,000	-68,000,000	-104,800,000	-52,700,000	-128,000,000	-147,000,000	-68,000,000			-50,000,000	0	0	-112,000,000	-100,200,000	0	0	-30,000,000	-20,000,000				-88,000,000	-211,300,000			-15,100,000	-125,100,000	-302,000,000	-152,500,000	-25,000,000	-350,100,000	-131,400,000	-422,000,000
proceeds from held-to-maturity investments	14,300,000	17,700,000		25,200,000	15,900,000	9,300,000		8,000,000	3,000,000	80,500,000		47,000,000	147,500,000	130,000,000		20,000,000	0	50,000,000		0	112,000,000	100,200,000		0	30,000,000	20,000,000	190,000,000	48,600,000	101,000,000	238,500,000	321,700,000	101,000,000	2,500,000	229,500,000	223,800,000	281,400,000	92,300,000	255,000,000	125,000,000	572,500,000	231,700,000	330,900,000
purchases of available-for-sale investments	-624,300,000	-634,500,000	-381,100,000	-517,000,000	0	-1,800,000	-700,000	-1,600,000	-3,600,000	-3,200,000	-13,000,000	-188,500,000	-40,200,000	-74,100,000	-907,300,000	-345,500,000	-299,100,000	-77,400,000	-295,400,000	-118,600,000
proceeds from available-for-sale investments	611,800,000	827,900,000		150,700,000	231,100,000	157,300,000		172,400,000	131,100,000	183,400,000		177,000,000	212,100,000	372,000,000		93,600,000	81,700,000	86,800,000		103,300,000	127,200,000	127,800,000		87,500,000	134,700,000	56,100,000	30,100,000	92,000,000	58,800,000	42,300,000	67,700,000	91,600,000	96,100,000	193,300,000	71,500,000	66,300,000	47,100,000	47,700,000	53,300,000	48,300,000	59,700,000	18,300,000
investments in intangible assets			-4,600,000	-5,400,000	0	-20,000,000																		0	-7,200,000	-16,800,000
payment for working capital adjustment for sale of product group	0	-36,300,000
payment for acquisition options	-14,000,000	-3,000,000		-5,400,000	0	-10,800,000		0	0	-15,000,000		-52,100,000
issuances of notes receivable	-52,800,000	-17,800,000	-35,000,000	-10,500,000	-15,000,000	-2,500,000	-15,000,000	-25,000,000	-7,500,000	-15,000,000	-800,000	-6,000,000	-35,000,000	-10,500,000	-1,500,000	0	0	-3,600,000	-500,000	-4,600,000	-5,300,000	-16,600,000
net cash from investing activities	-172,100,000	85,300,000	-576,700,000	2,701,700,000	124,800,000	63,100,000	14,100,000	89,000,000	70,200,000	500,000	94,700,000	-201,500,000	129,600,000	229,500,000	-965,900,000	-377,400,000	-329,500,000	-49,700,000	-259,900,000	-126,300,000	-10,200,000	-134,700,000	-445,300,000	-12,700,000	-88,300,000	-49,500,000	5,700,000	-254,200,000	104,900,000	220,300,000	49,300,000	-209,500,000	-638,200,000	151,200,000	80,200,000	3,900,000	-343,100,000	47,300,000	27,300,000	-175,600,000	12,500,000	-180,300,000
cash flows from financing activities
purchases of treasury stock	-5,500,000	-258,600,000	-100,100,000	-901,000,000	-158,100,000	-200,000	-448,400,000	-174,400,000	-7,500,000	-249,300,000	-866,000,000	-100,400,000	-355,100,000	-405,600,000	-96,500,000	-1,800,000	-111,900,000	-302,600,000	-200,000	-1,400,000	-9,000,000	-614,800,000	0	-1,300,000	-256,300,000	-5,700,000	-272,000,000	-173,100,000	-348,200,000	-2,200,000	-251,300,000	-800,000	-73,800,000	-437,400,000	-281,400,000	-200,000	-36,600,000	-344,100,000	-100,000,000	-200,000	-78,900,000	-101,000,000
equity forward contract related to accelerated share repurchase agreement	0	-50,000,000																																		0	22,500,000	-57,500,000
proceeds from stock plans	57,200,000	49,900,000	28,600,000	34,500,000	54,300,000	62,100,000	33,200,000	34,000,000	60,800,000	41,900,000	27,500,000	32,400,000	49,000,000	37,500,000	33,900,000	38,900,000	54,200,000	31,600,000	37,000,000	36,100,000	38,300,000	29,100,000	35,000,000	39,000,000	41,500,000	45,000,000	27,700,000	35,000,000	39,600,000	44,700,000	22,500,000	22,600,000	45,600,000	23,100,000	20,600,000	38,100,000	25,100,000	19,500,000	27,200,000	17,500,000	19,000,000	23,500,000	9,200,000	11,700,000	8,300,000	10,200,000	7,700,000	-14,699,977.9
net cash from financing activities	52,700,000	-258,000,000	28,600,000	-976,700,000	-96,600,000	61,700,000	-413,200,000	-143,300,000	52,100,000	-206,600,000	-838,400,000	-69,900,000	-308,100,000	-368,100,000	-62,000,000	39,000,000	-59,000,000	-274,300,000	41,400,000	34,000,000	24,100,000	-586,400,000	37,000,000	34,400,000	-231,400,000	44,400,000	-844,700,000	-56,700,000	-240,700,000	40,900,000	-229,000,000	20,300,000	126,800,000	-391,300,000	5,100,000	63,800,000	31,700,000	-369,100,000	-59,700,000	23,600,000	-50,600,000	-71,900,000
effect of currency exchange rate changes on cash, cash equivalents, and restricted cash	-29,600,000	-17,700,000	51,000,000	-51,500,000	29,400,000	9,700,000	-3,400,000	9,200,000	15,200,000	-4,200,000	-18,200,000	10,300,000	13,900,000	13,200,000	1,800,000	500,000	-2,600,000	14,200,000
net increase in cash, cash equivalents, and restricted cash	141,200,000	90,000,000	-624,600,000	2,025,300,000	429,100,000	81,000,000	-265,900,000	366,400,000	171,100,000	103,800,000	-479,100,000	48,800,000	167,600,000	167,900,000	-652,500,000	194,000,000
cash, cash equivalents, and restricted cash at beginning of period	0	3,058,800,000		0	0	1,148,000,000		0	0	772,600,000		0	0	867,400,000		0	0	1,200,200,000
cash, cash equivalents, and restricted cash at end of period	141,200,000	3,148,800,000		2,025,300,000	429,100,000	1,229,000,000		366,400,000	171,100,000	876,400,000		48,800,000	167,600,000	1,035,300,000		194,000,000	135,000,000	1,190,900,000
gain on investments		12,500,000									2,400,000	10,900,000																					-2,200,000	-1,500,000		-1,400,000	-700,000	-300,000
gain on sale of product group
impairment charges
change in fair value of contingent consideration liabilities							0	0	-26,900,000	700,000	500,000	-12,500,000	-20,900,000	-2,900,000	-18,100,000	1,100,000	-102,600,000	-4,500,000	5,200,000	-9,000,000	19,600,000	-2,200,000	-18,500,000	-2,300,000	8,000,000	6,700,000	-14,000,000	-6,400,000	10,900,000	3,800,000	2,600,000
(gain) loss on investments																																								-1,100,000	-300,000	-1,100,000
gain on remeasurement of previously held equity interest upon acquisition
long-term prepaid royalties			2,100,000	2,000,000			2,000,000	2,100,000
proceeds from sales and maturities of held-to-maturity investments
proceeds from sales and maturities of available-for-sale investments
business combinations, net of cash
payments for acquisition options
collections of notes receivable											0	0	0	18,000,000	10,000,000	0
proceeds from sale of product group
cash, cash equivalents, and restricted cash at beginning of year
cash, cash equivalents, and restricted cash at end of year
gain on sale of business
gain on remeasurement of previously held interest upon acquisition
proceeds from sale of business																																																-9,199,990.8
business combination, net of cash							46,000,000	0	0	-141,200,000
proceeds from issuance of debt															0	-8,800,000	9,500,000	4,500,000	3,900,000	1,700,000	2,700,000	7,900,000	6,900,000	2,300,000	6,000,000	3,700,000	1,600,000	600,000	680,700,000	5,100,000	5,400,000	3,900,000	608,000,000	377,400,000	228,900,000	8,700,000	6,200,000	9,700,000	10,700,000	7,400,000	5,900,000	7,400,000
payments on debt and finance lease obligations											-100,000	0			-100,000	8,700,000	-10,700,000	-4,900,000	-3,000,000	-2,200,000	-3,600,000	-8,200,000
adjustments to reconcile net income to net cash from operating activities
impairment charge
loss on investments
adjustments to reconcile net income to cash from operating activities:
litigation settlement accrual											-8,900,000	-16,400,000	-9,700,000	-10,000,000	-10,100,000	-22,800,000	2,100,000	1,600,000	1,300,000	-98,700,000
payment for acquisition option															-7,400,000	0			0	0			0	0	0	-35,000,000
inventory write off																							0
purchased in-process research and development																															0	1,000,000	100,000	5,600,000	0	0
acquisition																								0
investments in intangible assets and in-process research and development																													0	-3,000,000	0	-1,000,000	-3,700,000	-2,700,000	0	-200,000
net decrease in cash, cash equivalents, and restricted cash																		-9,300,000
payment of contingent consideration																											0	0	0	-10,000,000
purchase of intellectual property																								0	0	24,000,000
effect of currency exchange rate changes on cash and cash equivalents																				-3,300,000	-4,500,000	-2,100,000	1,400,000	800,000	-3,900,000	-1,300,000	-1,200,000	3,500,000	-5,000,000	-3,800,000	3,800,000	500,000	2,600,000	1,000,000	-1,300,000	1,500,000	-10,400,000	-2,300,000	900,000	-2,000,000	8,600,000	-17,900,000			500,000
net increase in cash and cash equivalents																				120,500,000			-7,500,000	459,800,000	17,600,000	-4,900,000	-547,200,000	34,900,000	-600,000	408,700,000																	10,600,000	-47,199,960.9
cash and cash equivalents at beginning of period																				0	0	1,179,100,000		0	0	714,100,000		0	0	818,300,000		0	0	930,100,000		0	0	718,400,000		0	0	653,800,000	0	182,800,000	0	0	178,600,000	-48,899,951.1
cash and cash equivalents at end of period																				120,500,000	240,600,000	662,900,000		459,800,000	17,600,000	709,200,000		34,900,000	-600,000	1,227,000,000		122,100,000	-311,100,000	819,300,000		275,100,000	-131,500,000	501,400,000		48,500,000	140,600,000	457,000,000	-15,300,000	180,200,000	-15,800,000	-22,100,000	189,200,000	-96,099,912
purchases of available-for sale investments																						-150,900,000		-19,600,000								-145,500,000	-164,900,000	-167,400,000		-162,200,000	-101,400,000	-73,400,000		-100,600,000	-122,000,000	-84,600,000
investments in trading securities																						300,000				-1,900,000			-1,600,000	-3,100,000	-4,700,000	-2,200,000	-1,400,000	-4,400,000	-3,300,000	-1,300,000	-1,200,000	-4,000,000	-2,900,000	-1,500,000	-2,800,000	-2,000,000
net decrease in cash and cash equivalents																						-516,200,000										122,100,000	-311,100,000	-110,800,000		275,100,000	-131,500,000	-217,000,000				-196,800,000
deposit of cash in escrow
acquisitions
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
payments on debt and capital lease obligations																								-3,500,000	-16,200,000	-4,000,000	-601,200,000	-1,900,000	-517,100,000	-5,100,000	-5,600,000	-4,600,000	-454,800,000	-353,400,000	-5,700,000	-6,400,000	-9,800,000	-9,500,000	-10,700,000	-4,100,000	-6,500,000	-8,200,000
inventory reserves
balance at december 31, 2018
other comprehensive income, net of tax
common stock issued under equity plans
stock-based compensation expense
balance at march 31, 2019
balance at june 30, 2019
balance at december 31, 2017
impact to retained earnings from adoption of asu 2016-16 and asu 2018-02
balance at january 1, 2018
other comprehensive loss, net of tax
balance at march 31, 2018
shares issued in payment for contingent consideration liabilities
balance at june 30, 2018
amortization of right-of-use-assets																										5,700,000
excess tax benefit from stock plans																																			-7,700,000	-19,400,000	-26,100,000	-11,100,000	-14,200,000	-7,400,000	-9,900,000	-9,800,000	1,400,000	3,700,000	1,600,000	1,700,000	600,000
proceeds from unconsolidated affiliates
acquisition of business, net of cash acquired																																-100,000	-2,800,000	-82,000,000
supplemental disclosures:
non-cash investing and financing transactions:
fair value of shares issued in connection with business combinations																															0	0	0	266,500,000
capital expenditures accruals																														15,800,000	2,500,000	2,900,000	3,400,000	12,800,000	3,000,000	2,500,000	800,000	16,400,000	5,200,000	1,100,000	2,200,000	6,600,000
cash paid during the year for:
interest
retirement of treasury stock																															0
impairment and other charges
proceeds from sale of assets																																											0	2,400,000
capital additions transferred from inventory
capital lease obligations incurred
special gains
accounts receivable securitization																																											1,300,000	3,300,000
prepaid expenses
acquisition milestone payment
proceeds from issuance of long-term debt																																											12,700,000	17,600,000	12,900,000	16,300,000	12,800,000	-99,599,782.2
payments on long-term debt
special charges
proceeds from sale of product lines																																													0
proceeds from asset dispositions																																																-1,399,998.6
supplemental disclosure of non-cash activities
installment purchase of patents																																																-7,999,992
special gains, net of charges
proceeds from sale of businesses																																															5,700,000
proceeds from accounts receivable securitization
other investing activities
other financing activities
supplemental disclosure of non-cash activities:

We provide you with 20 years of cash flow statements for Edwards Lifesciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Edwards Lifesciences stock. Explore the full financial landscape of Edwards Lifesciences stock with our expertly curated income statements.

The information provided in this report about Edwards Lifesciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.